Global Impetigo Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • ID: 4564302
  • Report
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Karalex Pharma, LLC
  • Leo Pharma A/S
  • Lupin Limited
  • Pfizer, Inc.
  • Roche Holding AG
  • MORE
Impetigo Treatment Market - Growth, Future Prospects and Competitive Analysis, 2018-2026, the global Impetigo treatment market was valued at US$ 448.6 Mn in 2017 and expected to reach US$ 856.2 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026.

Market Insights
The global impetigo treatment market identified to be worth US$ 856.2 Mn by 2026 from US$ 448.6 Mn in 2017, growing at a CAGR of 7.3% during the forecast period from 2018 to 2026. The impetigo is a superficial skin infection caused by gram-positive bacteria, Staphylococcus aureus or Streptococcus pyogenes. The infection is reported to be highly prevalent in children under the age of 14. According to Asha C. Bowen, et al. “The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma”. PLoS One 2015; 10(8), the global point-prevalence of impetigo has risen from 111 million in 2000 to 162 million in 2015, and the majority of the cases are observed in Oceania region particularly in low & middle-income countries. High point-prevalence of impetigo is the prime factor accounting to the surge of the impetigo treatment market. Additionally, the awareness regarding pediatric skin diseases and growing healthcare infrastructure fuel the market growth. Moreover, the evolving resistance of the microbes due to frequent usage is a prime concern and burdens the manufacturers to develop effective antibiotics, thereby accounting for market growth.

Based on the drug class, the global impetigo treatment market is segmented into cephalosporins, fusidane, lincosamide, penicillin, penicillin-like antibiotics, pleuromutilin, pseudomonic acid A, quinolone, sulfonamides and folic acid inhibitors, and tetracyclines. In 2017, penicillin segment dominated the global impetigo treatment market due to high preference by the physicians. Penicillin-like antibiotics segment tailed the penicillin segment and accounted for over 15% of the global share, in terms of value.

Based on geographical demarcation, in 2017, North America led the global market with over 34% of the market share, in terms of value, and expected to retain its lead during the forecast period. The well-established healthcare infrastructure and growing awareness regarding skin diseases are the prime factors for the supremacy of North America. Europe tailed North America followed by Asia Pacific region, in terms of value. Since the fusidane/fusidic acid is not available in the United States, so the treatment pattern vary from the European region.

The global impetigo treatment market witness the presence of numerous players as the treatment includes antibiotics only. Several global and local manufacturers compete in the market and form a fragmented market. Some of the key players in the market include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Karalex Pharma, LLC
  • Leo Pharma A/S
  • Lupin Limited
  • Pfizer, Inc.
  • Roche Holding AG
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I - Secondary Research
1.4.2. Phase II - Primary Research
1.4.3. Phase III - Expert Panel Review
1.4.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Impetigo Treatment Market Portraiture
2.2. Global Impetigo Treatment Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Impetigo Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Impetigo Treatment Market: Dynamics and Future Outlook
3.1. Overview
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Increasing Number of Impetigo Cases Leading to Growing Medical Attention
3.2.1.2. Driver 2
3.2.2. Challenges
3.2.2.1. Challenge 1
3.2.2.2. Challenge 2
3.2.3. Opportunities
3.2.3.1. Opportunity 1
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Impetigo Treatment Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Cephalosporins
4.3. Fusidane
4.4. Lincosamide
4.5. Penicillin
4.6. Penicillin-like Antibiotics
4.7. Pleuromutilin
4.8. Pseudomonic Acid A
4.9. Quinolone
4.10. Sulfonamides And Folic Acid Inhibitors
4.11. Tetracyclines
4.12. Pipeline Analysis
4.12.1. Phase III (Market estimations by 2026)
4.12.1.1. NVC-422 (NovaBay Pharmaceuticals)
4.12.2. Phase II & I (Tabular Information)

Chapter 5. Global Impetigo Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
5.2.1. North America Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.2.2. North America Impetigo Treatment Market, by Country, 2016 - 2026 (US$ Mn)
5.2.2.1. United States
5.2.2.2. Canada
5.3. Europe Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
5.3.1. Europe Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.3.2. Europe Impetigo Treatment Market, by Country/Region, 2016 - 2026 (US$ Mn)
5.3.2.1. United Kingdom
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
5.4.1. Asia Pacific Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.4.2. Asia Pacific Impetigo Treatment Market, by Country/Region, 2016 - 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
5.5.1. Latin America Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.5.2. Latin America Impetigo Treatment Market, by Country/Region, 2016 - 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
5.6.1. Middle East & Africa Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.6.2. Middle East & Africa Impetigo Treatment Market, by Region, 2016 - 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. GlaxoSmithKline plc
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Karalex Pharma, LLC
6.3. Leo Pharma A/S
6.4. Lupin Limited
6.5. NovaBay Pharmaceuticals, Inc.
6.6. Pfizer, Inc.
6.7. Ranbaxy Laboratories Limited
6.8. Roche Holding AG
6.9. SANDOZ GmbH
6.10. Taro Pharmaceutical Industries Ltd.
6.11. Teva Pharmaceutical Industries Ltd.

List of Figures
FIG. 1 Market Segmentation: Global Impetigo Treatment Market
FIG. 2 Research Methodology: Global Impetigo Treatment Market
FIG. 3 Global Impetigo Treatment Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global Impetigo Treatment Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: Global Impetigo Treatment Market, by Geography, 2017
FIG. 6 Competitive Landscape, by Key Players, 2017
FIG. 7 Global Cephalosporins Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 8 Global Fusidane Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 9 Global Lincosamide Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 10 Global Penicillin Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 11 Global Penicillin-like Antibiotics Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 12 Global Pleuromutilin Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 13 Global Pseudomonic Acid A Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 14 Global Quinolone Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 15 Global Sulfonamides And Folic Acid Inhibitors Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 16 Global Tetracyclines Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 17 Global NVC-422 Market for Impetigo Treatment, 2016 - 2026 (US$ Mn)
FIG. 18 U.S. Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 19 Canada Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 20 U.K. Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 21 Germany Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 22 Rest of Europe Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 23 China Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 24 Japan Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 25 Rest of Asia Pacific Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 26 Brazil Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 27 Mexico Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 28 Rest of Latin America Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 29 GCC Impetigo Treatment Market, 2016 - 2026 (US$ Mn)
FIG. 30 Rest of Middle East and Africa Impetigo Treatment Market, 2016 - 2026 (US$ Mn)

List of Tables
TABLE 1. Global Impetigo Treatment Market Portraiture
TABLE 2. Global Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 3. Global Impetigo Treatment Market, by Geography, 2016 - 2026 (US$ Mn)
TABLE 4. North America Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 5. North America Impetigo Treatment Market, by Country, 2016 - 2026 (US$ Mn)
TABLE 6. Europe Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 7. Europe Impetigo Treatment Market, by Country/Region, 2016 - 2026 (US$ Mn)
TABLE 8. Asia Pacific Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 9. Asia Pacific Impetigo Treatment Market, by Country/Region, 2016 - 2026 (US$ Mn)
TABLE 10. Latin America Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 11. Latin America Impetigo Treatment Market, by Country/Region, 2016 - 2026 (US$ Mn)
TABLE 12. Middle East and Africa Impetigo Treatment Market, by Drug Class, 2016 - 2026 (US$ Mn)
TABLE 13. Middle East and Africa Impetigo Treatment Market, by Region, 2016 - 2026 (US$ Mn)
TABLE 14. GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15. Karalex Pharma, LLC: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16. Leo Pharma A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17. Lupin Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18. NovaBay Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19. Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20. Ranbaxy Laboratories Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21. Roche Holding AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22. SANDOZ GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23. Taro Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24. Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline plc
  • Karalex Pharma, LLC
  • Leo Pharma A/S
  • Lupin Limited
  • NovaBay Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Ranbaxy Laboratories Limited
  • Roche Holding AG
  • SANDOZ GmbH
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll